Ligation of OX40 provides costimulation to activated T cells, increasing their survival and prolonging responses.49 Studies have observed Treg OX40 ligation to promote accumulation of quiescent Tregs and antagonise FOXP3 induction in naïve CD4+ T cells.49 Therefore, therapeutically targeting the OX40 axis to stimulate long‐term T‐cell responses and reduce Treg burden is an attractive target for treatment of lung cancers. The gene discussed is CD4; the disease is lung cancer.